Piramal Pharma Limited (PPLPHARMA) - Total Assets
Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) holds total assets worth Rs179.65 Billion INR (≈ $1.94 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore PPLPHARMA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Piramal Pharma Limited - Total Assets Trend (2021–2026)
This chart illustrates how Piramal Pharma Limited's total assets have evolved over time, based on quarterly financial data. See Piramal Pharma Limited (PPLPHARMA) shareholders funds for net asset value and shareholders' equity analysis.
Piramal Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Piramal Pharma Limited's total assets of Rs179.65 Billion consist of 40.0% current assets and 60.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 6.8% |
| Accounts Receivable | Rs21.58 Billion | 12.0% |
| Inventory | Rs30.64 Billion | 17.1% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs28.84 Billion | 16.1% |
| Goodwill | Rs12.57 Billion | 7.0% |
Asset Composition Trend (2021–2026)
This chart illustrates how Piramal Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PPLPHARMA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Piramal Pharma Limited's current assets represent 40.0% of total assets in 2026, an increase from 30.7% in 2021.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2026, up from 2.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 20.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 17.1% of total assets.
Piramal Pharma Limited Competitors by Total Assets
Key competitors of Piramal Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥7.80 Billion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Piramal Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.51 | 1.54 | 1.29 |
| Quick Ratio | 0.87 | 0.93 | 0.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs24.33 Billion | Rs20.31 Billion | Rs4.41 Billion |
Piramal Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Piramal Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.92 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 14.6% |
| Total Assets | Rs179.65 Billion |
| Market Capitalization | $3.00 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Piramal Pharma Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Piramal Pharma Limited's assets grew by 14.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Piramal Pharma Limited (2021–2026)
The table below shows the annual total assets of Piramal Pharma Limited from 2021 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs179.65 Billion ≈ $1.94 Billion |
+14.59% |
| 2025-03-31 | Rs156.78 Billion ≈ $1.70 Billion |
+2.39% |
| 2024-03-31 | Rs153.12 Billion ≈ $1.66 Billion |
+5.43% |
| 2023-03-31 | Rs145.23 Billion ≈ $1.57 Billion |
+13.48% |
| 2022-03-31 | Rs127.97 Billion ≈ $1.38 Billion |
+122.30% |
| 2021-03-31 | Rs57.57 Billion ≈ $622.56 Million |
-- |
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more